Ordered recruitment of chromatin modifying and general transcription factors to the IFN-β promoter T Agalioti, S Lomvardas, B Parekh, J Yie, T Maniatis, D Thanos Cell 103 (4), 667-678, 2000 | 999 | 2000 |
Structure of IRF-1 with bound DNA reveals determinants of interferon regulation CR Escalante, J Yie, D Thanos, AK Aggarwal Nature 391 (6662), 103-106, 1998 | 472 | 1998 |
Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15 JY Hsu, S Crawley, M Chen, DA Ayupova, DA Lindhout, J Higbee, ... Nature 550 (7675), 255-259, 2017 | 449 | 2017 |
Acetylation of HMG I (Y) by CBP turns off IFNβ expression by disrupting the enhanceosome N Munshi, M Merika, J Yie, K Senger, G Chen, D Thanos Molecular cell 2 (4), 457-467, 1998 | 442 | 1998 |
Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor γ isoforms E Mueller, S Drori, A Aiyer, J Yie, P Sarraf, H Chen, S Hauser, ED Rosen, ... Journal of Biological Chemistry 277 (44), 41925-41930, 2002 | 336 | 2002 |
Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN EY Tsai, J Yie, D Thanos, AE Goldfeld Molecular and Cellular Biology 16 (10), 5232-5244, 1996 | 257 | 1996 |
The role of HMG I (Y) in the assembly and function of the IFN-β enhanceosome J Yie, M Merika, N Munshi, G Chen, D Thanos The EMBO journal 18 (11), 3074-3089, 1999 | 240 | 1999 |
FGF21 N-and C-termini play different roles in receptor interaction and activation J Yie, R Hecht, J Patel, J Stevens, W Wang, N Hawkins, S Steavenson, ... FEBS letters 583 (1), 19-24, 2009 | 222 | 2009 |
Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes R Hecht, YS Li, J Sun, E Belouski, M Hall, T Hager, J Yie, W Wang, ... PloS one 7 (11), e49345, 2012 | 185 | 2012 |
Intra-and intermolecular cooperative binding of high-mobility-group protein I (Y) to the beta-interferon promoter J Yie, S Liang, M Merika, D Thanos Molecular and cellular biology 17 (7), 3649-3662, 1997 | 168 | 1997 |
Mechanism by which the IFN-β enhanceosome activates transcription J Yie, K Senger, D Thanos Proceedings of the national academy of Sciences 96 (23), 13108-13113, 1999 | 165 | 1999 |
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models EA Killion, J Wang, J Yie, SDH Shi, D Bates, X Min, R Komorowski, ... Science Translational Medicine 10 (472), eaat3392, 2018 | 151 | 2018 |
Understanding the Physical Interactions in the FGF21/FGFR/β‐Klotho Complex: Structural Requirements and Implications in FGF21 Signaling J Yie, W Wang, L Deng, LT Tam, J Stevens, MM Chen, Y Li, J Xu, ... Chemical biology & drug design 79 (4), 398-410, 2012 | 114 | 2012 |
Gene repression by coactivator repulsion K Senger, M Merika, T Agalioti, J Yie, CR Escalante, G Chen, ... Molecular cell 6 (4), 931-937, 2000 | 103 | 2000 |
The IFN-β enhancer: a paradigm for understanding activation and repression of inducible gene expression N Munshi, J Yie, M Merika, K Senger, S Lomvardas, T Agalioti, D Thanos Cold Spring Harbor symposia on quantitative biology 64, 149-160, 1999 | 85 | 1999 |
A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys S Stanislaus, R Hecht, J Yie, T Hager, M Hall, C Spahr, W Wang, ... Endocrinology 158 (5), 1314-1327, 2017 | 84 | 2017 |
Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation J Xu, J Bussiere, J Yie, A Sickmier, P An, E Belouski, S Stanislaus, ... Bioconjugate chemistry 24 (6), 915-925, 2013 | 78 | 2013 |
Antibodies to myostatin ER Chin, LL Green, C Ibebunjo, PA Krasney, J Yie, J Zachweija US Patent 7,807,159, 2010 | 75 | 2010 |
Antibodies to myostatin ER Chin, LL Green, C Ibebunjo, PA Krasney, J Yie, J Zachweija US Patent 7,807,159, 2010 | 75 | 2010 |
Antibodies to myostatin ER Chin, LL Green, C Ibebunjo, PA Krasney, J Yie, J Zachweija US Patent 7,807,159, 2010 | 75 | 2010 |